Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SVT 1A4710

X
Drug Profile

SVT 1A4710

Alternative Names: AVT-1A4710; SVT-1A4710 + immunosuppressants

Latest Information Update: 07 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servatus Biopharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 07 Mar 2023 Preclinical trials in Ulcerative colitis in Australia (unspecified route) (Servatus Biopharmaceuticals pipeline, March 2023)
  • 03 Feb 2021 Servatus Biopharmaceuticals holds published patents in World, China and Singapore, and pending applications in Europe, Canada, Japan, USA and Australia, related to microbial biotherapeutics for the treatment of various indications, including gastrointestinal and inflammatory diseases, prior to February 2021
  • 03 Feb 2021 Preclinical trials in Inflammatory bowel diseases in Australia (Servatus Biopharmaceuticals pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top